A1 Refereed original research article in a scientific journal
Transcatheter Aortic Valve Implantation in Low-Risk Tricuspid or Bicuspid Aortic Stenosis: The NOTION-2 Trial
Authors: Jørgensen, Troels Højsgaard; Thyregod, Hans Gustav Hørsted; Savontaus, Mikko; Willemen, Yannick; Bleie, Øyvind; Tang, Mariann; Niemelä, Matti; Angerås, Oskar; Gudmundsdóttir, Ingibjörg J; Sartipy, Ulrik; Dagnegaard, Hanna; Laine, Mika; Rück, Andreas; Piuhola, Jarkko; Petursson, Petur; Christiansen, Evald H; Malmberg, Markus; Olsen, Peter Skov; Haaverstad, Rune; Sondergaard, Lars; De Backer, Ole; for the NOTION-2 investigators
Publisher: Oxford University Press
Publication year: 2024
Journal: European Heart Journal
Journal name in source: European heart journal
Journal acronym: Eur Heart J
Volume: 45
Issue: 37
First page : 3804
Last page: 3814
ISSN: 0195-668X
eISSN: 1522-9645
DOI: https://doi.org/10.1093/eurheartj/ehae331
Web address : https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae331/7673297?login=true
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/404650535
Background and aims: Transcatheter aortic valve implantation (TAVI) has become the first choice to treat older patients with severe symptomatic aortic stenosis (AS). This study aimed to compare TAVI with surgery in low-risk patients ≤ 75 years of age, including both tricuspid and bicuspid AS.
Methods: The NOTION-2 trial enrolled and 1:1 randomized low-risk patients aged ≤ 75 years with severe symptomatic AS to TAVI or surgery. The primary endpoint was a composite of all-cause mortality, stroke or rehospitalization (related to the procedure, valve or heart failure) at 12 months.
Results: A total of 370 patients were enrolled with a mean age of 71.1 years and a median Society of Thoracic Surgeons risk score of 1.1%. A total of 100 patients had bicuspid AS. The 1-year incidence of the primary endpoint was 10.2% in the TAVI group and 7.1% in the surgery group (absolute risk difference 3.1%; 95% confidence interval [CI], -2.7% to 8.8%; hazard ratio (HR) 1.4, 95% CI: 0.7 to 2.9; p=0.3). Patients with TAVI, when compared to surgery, had lower risk of major bleeding and new-onset atrial fibrillation and higher risk of non-disabling stroke, permanent pacemaker implantation and moderate-or-greater paravalvular regurgitation. The risk of the primary composite endpoint was 8.7% and 8.3% in patients with tricuspid AS (HR 1.0, 95% CI: 0.5 to 2.3) and 14.3% and 3.9% in patients with bicuspid AS (HR 3.8, 95% CI: 0.8 to 18.5) treated with TAVI or surgery, respectively (P for interaction=0.1).
Conclusions: Among low-risk patients aged ≤ 75 years with severe symptomatic AS, the rate of the composite of death, stroke, or rehospitalization at one year was similar between TAVI and surgery. TAVI outcomes in young bicuspid AS patients warrant caution and should be further investigated. (NOTION-2, ClinicalTrials.gov, NCT02825134).
Downloadable publication This is an electronic reprint of the original article. |